Australian inflammatory diseases specialist Dimerix (ASX: DXB) has received an initial payment of 6.5 million euros ($7 million) in line with the recently-announced license agreement with Advanz Pharma.
Under the agreement, Advanz has been granted exclusive rights to commercialize DMX-200 for the kidney disease focal segmental glomerulosclerosis (FSGS) in the European Economic Area, the UK, Switzerland, Canada, Australia, and New Zealand.
Dimerix has retained all commercial rights to DMX-200 outside the Advanz territories, as well as all other indications globally.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze